Humacyte FY2024 EPS Estimate Reduced by Cantor Fitzgerald

Humacyte, Inc. (NASDAQ:HUMA) – Equities research analysts at Cantor Fitzgerald dropped their FY2024 earnings per share (EPS) estimates for shares of Humacyte in a research note issued on Monday, November 11th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings per share of ($1.41) for the year, down from their previous estimate of ($1.23). Cantor Fitzgerald currently has a “Overweight” rating and a $13.00 price objective on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($1.18) per share.

Other research analysts have also recently issued reports about the stock. EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a report on Monday, September 9th. BTIG Research restated a “buy” rating and set a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. Benchmark restated a “buy” rating and set a $15.00 target price on shares of Humacyte in a research report on Thursday, October 10th. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Humacyte in a research report on Wednesday. Finally, TD Cowen reissued a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $11.00.

Humacyte Trading Down 0.4 %

NASDAQ:HUMA opened at $5.34 on Thursday. The stock has a fifty day moving average price of $5.45 and a two-hundred day moving average price of $6.18. The company has a current ratio of 1.10, a quick ratio of 5.41 and a debt-to-equity ratio of 0.61. Humacyte has a 1 year low of $2.25 and a 1 year high of $9.97.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04).

Insider Activity

In other Humacyte news, Director Brady W. Dougan sold 352,112 shares of Humacyte stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $6.35, for a total value of $2,235,911.20. Following the completion of the sale, the director now directly owns 3,677,262 shares of the company’s stock, valued at approximately $23,350,613.70. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Humacyte news, Director Brady W. Dougan sold 352,112 shares of the firm’s stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $6.35, for a total value of $2,235,911.20. Following the sale, the director now directly owns 3,677,262 shares of the company’s stock, valued at approximately $23,350,613.70. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Laura E. Niklason sold 277,090 shares of Humacyte stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $6.47, for a total value of $1,792,772.30. Following the completion of the sale, the chief executive officer now owns 4,029,374 shares of the company’s stock, valued at $26,070,049.78. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,084,153 shares of company stock valued at $6,869,996 over the last 90 days. Insiders own 11.20% of the company’s stock.

Hedge Funds Weigh In On Humacyte

Large investors have recently bought and sold shares of the stock. nVerses Capital LLC purchased a new position in shares of Humacyte in the 2nd quarter worth about $28,000. Concurrent Investment Advisors LLC acquired a new stake in Humacyte during the 3rd quarter worth approximately $75,000. Principal Financial Group Inc. purchased a new position in Humacyte in the second quarter valued at approximately $83,000. FORA Capital LLC acquired a new position in Humacyte during the third quarter valued at approximately $96,000. Finally, Profund Advisors LLC purchased a new stake in Humacyte during the second quarter worth approximately $97,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.